Insulin-like growth factors I and II (IGF-I and IGF-II) are multifunctional peptides essential for normal growth and development (1) . Their biological actions are mediated by the type-I IGF receptor (2) and possibly the type-II IGF receptor, which is identical to the cation-independent mannose 6-phosphate receptor (3) . In the circulation and interstitial fluids, including the cerebrospinal fluid (CSF), IGFs are almost entirely associated with one or more of at least six IGF-binding proteins (IGFBPs) that bind IGFs with high affinity, thus limiting their interaction with receptors, and potentially providing a ''reservoir'' of biologically inactive IGF (1) . IGFs undoubtedly play an important role in brain development and may also be important after injury. IGF treatment protects the developing or adult brain from hypoxic-ischemic injury (4) (5) (6) (7) and forebrain ischemia (8) , induces myelination (9) (10) (11) , and reduces neuronal death in vitro caused by diverse forms of injury (12) (13) (14) (15) (16) . Paradoxically, injury to the developing or adult brain is commonly associated with increases in brain IGFs as well as their associated binding proteins (4, (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . Consequently, even though IGFs are elevated, they may be complexed with their binding proteins and unavailable to provide neuroprotection. The IGF system, therefore, provides a rather unique opportunity for utilizing an endogenous neuroprotective factor. We hypothesized that displacement of the large ''pool'' of IGF from the IGFBPs in the brain would elevate ''free'' IGF levels, increasing receptor activation to elicit similar actions to administration of IGF-I itself.
In the present studies, we examined the role of brain IGFs and IGFBPs in neuroprotection by comparing the effects of hIGF-I with the selective, high-affinity IGFBP ligand inhibitor, [Leu 24, 59, 60 , Ala 31 ]hIGF-I in in vitro studies of release of ''free'' bioactive IGF-I from rat cerebrospinal fluid and in in vivo studies to evaluate their neuroprotective effects in a rat model of focal ischemia. Data suggest that IGFBPs, by neutralizing IGFs, may serve to limit the actions of the peptides under both physiological and pathological conditions. Furthermore, the results demonstrating potent neuroprotective effects of the IGFBP ligand inhibitor comparable to IGF-I suggest that this strategy for increasing ''free'' IGF levels in the brain may be useful for the treatment of stroke and other neurodegenerative diseases. ]hIGF-I were synthesized by a solid-phase peptide synthesis procedure as described previously (27) by using a t-butoxycarbonyl-Ala-(oxymethyl)-phenylacetamidomethyl (PAM) resin on a Beckman 990 peptide synthesizer. Derivatized amino acids and resin used in the synthesis were purchased from Bachem. After the last residue was coupled onto the growing peptide chain, the protected peptide resin was treated with the low-high hydrogen fluoride cleavage procedure (28) to remove the peptide from the resin anchor and deprotect the side-chain functional groups. The crude peptide was extracted with 5 M guanidine HCl in 0.1 M NH 4 OAc, and the pH of the extract was maintained at 5 with HOAc. After filtering off the resin, the solution was diluted with 0.1 M NH 4 OAc to 2 M guanidine HCl to a peptide concentration of Ϸ1 mg͞ml. The peptide was cyclized by air oxidation by stirring at room temperature for 24 h while maintaining the pH at 8.4 with 10% concentrated NH 4 OH. After oxidation, the pH was adjusted to 5 and the solution was dialyzed against 0.1 M acetic acid at room temperature to remove the guanidine salt. The recovered dialysate was lyophilized and the crude product was purified by gel filtration on Sephadex G-50F, followed by carboxymethyl cellulose cationexchange chromatography and preparative HPLC on a KP-100 Gradient HPLC system with a Vydac C18 cartridge (Biotage, Charlottesville, VA). The purified product was verified by mass spectrometric analysis on a SCIEX͞AP1 LC͞MS system equipped with an ion-spray source (Perkin-Elmer).
MATERIALS AND METHODS

Synthesis
Radioligand Binding Assay. Human IGFBP-1, BP-4, and BP-5 were expressed in the BaculoGold Expression System (PharMingen) in Sf9 insect cells and purified by affinity chromatography on a hIGF-I-coupled Affi-Gel 10 column, followed by reverse-phase HPLC. Human IGFBP-2 and BP-3 were isolated from outdated plasma as described previously (29) . The binding assay was performed at room temperature in duplicate in 0.02% Nonidet P-40͞PBS buffer, pH 7.2. Two hundred microliters of a 2.5 nM IGFBP solution (0.5 pmol) was added to a 12 ϫ 75-mm glass test tube. The reaction was started by the addition of 100 l buffer, hIGF-I, hIGF-II, or [Leu 24, 59 ,60 , Ala 31 ]hIGF-I solution, followed by 100 l of [ 125 I]hIGF-I (30,000 cpm, specific activity Ϸ2,200 Ci͞mmol; New England Nuclear). After incubation for 2 h, 100 l of 20% BSA and 500 l of 20% PEG-8000 in the PBS buffer were added and the mixture was vortexed and then centrifuged for 30 min at 3,000 rpm. The supernatant was carefully removed by suction and the pellet was counted in a ␥-counter.
Radioligand and Western Blot Analysis of the IGF-Binding Proteins. Twenty microliters of rat CSF was fractionated by SDS͞PAGE and blotted onto nitrocellulose paper, and the blot was then incubated with [ 125 I]hIGF-I and examined by autoradiography according to the procedure described previously (30) . Western blot analysis of the IGFBPs was performed by electrophoresing 20 l of rat CSF per lane on SDS͞PAGE, followed by blotting of the gel onto nitrocellulose paper, according to the published procedure (30). The nitrocellulose paper was then cut into replicate strips, and one strip was incubated with IGFBP-2 antiserum (Upstate Biotechnology, Lake Placid, NY) whereas the other was incubated with IGFBP-5 antiserum raised in a rabbit with a synthetic peptide fragment as described previously (30) . The stained bands were revealed by incubation with peroxidase-conjugated goat antirabbit IgG, followed by chemiluminescence detection with a commercial kit (Pierce).
Gel Filtration Analysis of Dissociated IGF-I from the IGF-I͞IGF-Binding Protein Complex.
Five hundred microliters of rat CSF was incubated with [ 125 I]hIGF-I at 37°C for 1 h to incorporate the radioiodinated peptide into the complex, and the incubated fluid was divided into 100-l aliquots. To each aliquot was added buffer (control), IGF-I, or [Leu 24,59,60 , Ala 31 ]hIGF-I, and the mixture was incubated for 1 h at 37°C, followed by storage on ice. For gel-filtration analysis, each aliquot was diluted with 400 l 0.02% NaN 3 ͞0.1% BSA͞PBS buffer and the diluted sample was loaded onto a 1 ϫ 50 cm Sephadex G-50F column; the column was developed with the same buffer at a flow rate of 0.5 ml͞min at room temperature. The collected fractions were counted in a ␥-counter.
Fibroblast Proliferation Assay. ]hIGF-I were tested in a BALB͞c 3T3 fibroblast assay (31) . The ability of the peptides to induce proliferation was measured by counting the amount of [ 3 H]thymidine incorporated by the cells. Cells were aliquoted to 96-well microtiter plates (180 l per well). After a 48-h incubation at 37°C and 5% CO 2 , the plates were washed twice with 0.1% calf serum͞DMEM and incubated for an additional 24 h. Twenty microliters of sample and 1 Ci [ 3 H]thymidine (New England Nuclear) were added to each well, and the plates were incubated for a further 24 h. After incubation, the medium was removed and the cells were fixed by the addition of 200 l of a 25% acetic acid͞75% ethanol solution per well. After removal of the fixing solution, the plates were washed three times with cold 10% trichloroacetic acid and the cells were lysed in 200 l 0.2 M NaOH. The entire 200 l of lysate solution was transferred into a scintillation vial; 2.5 ml of scintillation liquid was added and the vials were counted in a ␥-counter.
Rat Middle Cerebral Artery Occlusion Model of Focal Ischemia. Male Sprague-Dawley rats (Charles River) were housed in a 12-h light͞12-h dark cycle and allowed food and water ad libitum. The experiment protocol was approved by the Institutional Animal Care and Use Committee in accordance with National Institutes of Health guidelines. Rats weighing 160-190 g were anesthetized with isoflurane (4% induction, 2.2% maintenance) in O 2 , and indwelling guide cannulae were stereotaxically implanted in the right, lateral ventricle [coordinates in mm: lateral (ϩ1.5); anteroposterior (Ϫ0.8); dorsoventral (Ϫ3.0), relative to Bregma] to permit subsequent injections into the CSF. Ten days later, rats were reanesthetized with halothane (4% induction, 2-2.5% maintenance) in O 2 , and focal cerebral ischemia was induced by permanent occlusion of the left, middle cerebral artery (MCAo) proximal to the lenticulostriate branch, by electrocoagulation. Throughout surgery and recovery from anesthesia, animals were maintained normothermic by means of a heated blanket. Peptides or vehicle (sterile water) were injected into the lateral ventricle (in a volume of 5 l) over 2-3 min, either concurrent with or 1 h after MCAo. One day after MCAo, animals were killed and the brains were removed. Delineation of the lesion was determined on fresh 500-m coronal brain sections incubated in 2% tri-phenyl-tetrazolium chloride (TTC; Sigma) by using an indirect approach thus ''correcting'' for any swelling. Lesion volume was calculated for each brain by integration of the areas of infarct in each section. These procedures are described in more detail elsewhere (32) . Peptide-treated groups were compared with vehicle-treated animals by using Student's unpaired t test.
RESULTS AND DISCUSSION
Before this study, Bayne et al. (33) (Table 1) . Furthermore, in contrast to hIGF-I, which dose-dependently stimulated ]hIGF-I, to displace the bound IGF-I and elevate ''free'' biologically active levels of the peptide in rat CSF and in the BALB͞c 3T3 fibroblast proliferation assays. In agreement with previous reports (36, 37), using ligand and Western blot analyses, we determined that the most abundant IGFBP in rat CSF is BP-2 ( Fig. 1 A and B, respectively) . Gel filtration analysis of rat CSF that had been preincubated with trace quantities of [ (Fig. 2) . The higher concentration of the IGFBP ligand inhibitor than IGF-I required to increase ''free'' IGF-I levels is in keeping with the Ϸ10-to 20-fold lower affinity of the IGFBP ligand inhibitor for IGFBPs than IGF-I itself ( Table 1 ). The ability of the IGFBP ligand inhibitor to release bioactive IGF-I was further evaluated in the 3T3 fibroblast assay. Human IGF-I (3 nM) produced robust proliferation of 3T3 fibroblasts as reflected by increased [ 3 H]thymidine incorporation; the hIGF-I-induced proliferation was substantially blocked by addition of 20 nM IGFBP-2 (Fig. 3) . The addition of [Leu 24,59,60 , Ala 31 ]hIGF-I dose-dependently reversed the neutralizing effect of IGFBP-2 on IGF-I (ED 50 ϭ 200 nM), demonstrating the ability of the IGFBP ligand inhibitor to displace hIGF-I bound to IGFBP-2 (Fig. 3) . Overall, these in vitro data clearly demonstrate that the IGFBP ligand inhibitor is capable of interacting with the binding protein in a specific manner to displace complexed IGF-I and release ''free'' bioactive peptide.
In view of the potent neuroprotective and regenerative effects of IGFs (4-16), we tested the hypothesis that displacement of IGF from its BPs in the brain could confer neuroprotection in a clinically relevant model of stroke in the rat. Although the models of ischemia [hypoxic-ischemia (4-7) and forebrain ischemia (8) ] previously used to evaluate the effects of IGF-I provide important information on the effects of ischemia on the brain, they are not considered as models of stroke. It is generally accepted that occlusion of a single intracranial artery (the middle cerebral artery, MCA) provides the best model to study stroke (38) ]hIGF-I (50 g) or the IGFBP ligand inhibitor (50 g) at the time of MCAo had much smaller total lesion volumes than those injected with vehicle, primarily because of a reduction of the cerebral cortical infarct volume, although some protection was also evident in the striatum (Fig. 4A) . The extent of neuroprotection (40-50%) was comparable for [Nle 59 ]hIGF-I and the IGFBP ligand inhibitor and is in keeping with that seen after treatment with NMDA receptor antagonists (39, 40) . Remarkably, the extent of protection was similar whether [Nle 59 ]hIGF-I or [Leu 24, 59, 60 , Ala 31 ]hIGF-I was administered concurrent with (0 h) or 1 h after occlusion of the artery (Fig. 4B) , providing a therapeutic window for the treatment as is available in this rat model of ischemia. In the more slowly developing hypoxic-ischemia model, IGFs confer neuroprotective effects when administered up to 2 h after the insult (4-7). These observations taken together with previous data indicating that i.c.v. injection of 50 g hIGF-I has no impact on plasma glucose levels or body temperature of ischemic rats (7) suggest that IGFs protect neurons by interfering with the pathological pathways that are initiated after ischemia.
The mechanisms through which the IGFBP ligand inhibitor and IGFs produce their neuroprotective effects are at present unclear. Ischemic neuronal damage has been attributed, in part, to the extracellular accumulation of excitatory amino acids; in preliminary studies done in our laboratory, the IGFBP ligand inhibitor [Leu 24, 59, 60 , Ala 31 ]hIGF-I attenuated the loss of pyramidal neurons in the hippocampus after intrahippocampal administration of quinolinic acid. In addition to producing their neuroprotective effects by interfering with endogenous mediators of ischemia such as glutamate, IGFs have the distinct advantage of also having the ability to act as regenerative growth factors. The IGFBP ligand inhibitor is capable of increasing the release of not only IGF-I but also IGF-II, which also has neuroprotective effects (13) Proc. Natl. Acad. Sci. USA 95 (1998) marked contrast to the effects of a CRF-receptor agonist, CRF-binding protein ligand inhibitors do not induce anxiety (42) , stimulate adrenocorticotropic hormone secretion, or elevate heart rate and blood pressure (44) . A further advantage in targeting IGFBPs is that it may be possible to identify nonpeptide small molecules that act as IGFBP ligand inhibitors, with the potential for good blood-brain barrier penetration and oral activity. In summary, our data demonstrate that pharmacological elevation of ''free'' endogenous IGFs in the brain confers protection in a clinically relevant model of stroke. Because of the dramatic protection observed with this strategy, even when treatment is delayed for 1 h after occlusion of the artery, these data suggest that displacement of IGFs from IGFBPs in the brain is a potential treatment for stroke. Moreover, in view of the potent actions of IGFs on survival of neurons and glial cells as well as the widespread protective effects against a variety of brain insults, IGFBP ligand inhibitors may have broader utility for the treatment of various neurodegenerative disorders as well as traumatic brain and spinal cord injury.
